NRXS vs NUVB

Neuraxis, Inc. vs Nuvation Bio Inc. — Valuation Comparison 2026

NRXS

Biotechnology
Neuraxis, Inc.
Quality
6.9
out of 10
Value Trap
18
SAFE
Price
$7.29
Last close
Models
10/13
Active
VS

NUVB

Biotechnology
Nuvation Bio Inc.
Quality
5.4
out of 10
Value Trap
30
LOW
Price
$4.75
Last close
Models
11/13
Active

Model-by-Model Comparison

ModelType NRXS Fair ValueNRXS Upside NUVB Fair ValueNUVB Upside
Bayesian DCF Intrinsic $2.04 -72.0% $1.26 -73.5%
Earnings Power Value Intrinsic $1.57 -80.6% $0.23 -94.9%
EROIC Spread Intrinsic $•••.•• ••.•% $•••.•• ••.•%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $•••.•• ••.•% $•••.•• ••.•%
Dynamic NAV Asset-Based $•••.•• ••.•% $•••.•• ••.•%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for NRXS vs NUVB — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

NRXS vs NUVB — Which Stock Is More Undervalued?

NRXS scores higher with a 6.9/10 quality rating vs NUVB's 5.4/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Neuraxis, Inc. (NRXS) and Nuvation Bio Inc. (NUVB) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

NRXS currently trades at $7.29 with a QOC of 6.9/10, while NUVB trades at $4.75 with a QOC of 5.4/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).